Navigation Links
Telik Announces First Quarter 2008 Financial Results
Date:5/8/2008

PALO ALTO, Calif., May 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $9.8 million, or $0.19 per share, for the first quarter ended March 31, 2008, compared with a net loss of $16.3 million, or $0.31 per share, for the comparable period in 2007.

For the quarter ended March 31, 2008, total operating costs and expenses were $10.6 million, compared with $18.0 million during the 2007 first quarter. Operating expenses in the 2008 first quarter included stock-based compensation expense of approximately $1.4 million. Operating expenses were 41% lower in the first quarter of 2008 compared with the year-ago quarter primarily as a result of reduced clinical trial and related expenses, lower headcount and lower stock-based compensation expense.

At March 31, 2008, Telik had $82.5 million in cash, cash equivalents and investments including restricted investments, compared to $93.2 million at December 31, 2007.

Conference Call and Webcast

Telik will conduct its quarterly conference call today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-230-1085 or 612-332-1214. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 920773. The archive will be available from approximately 6:30 p.m. Eastern time on May 8 through May 20, 2008.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for th
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , ... , a leader in synthetic biology, and ... drug manufacturer by volume in the U.S., today ... Collaboration (ECC) for a target active pharmaceutical ingredient ... goal of the collaboration is to develop a ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider ... technology, today announced its participation in the 2014 Big ... Data solutions provide semantic linkage and meaning to Big ... and manage diverse data. Ben Szekely, vice president and ... a “life sciences data lake” and an approach for ...
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Boston Scientific Corporation (NYSE: BSX ) today ... and Drug Administration (FDA) to market its TAXUS(R) Liberte ... deliverable, next-generation drug-eluting stent (DES) specifically designed for treating ... in vessels as small as 2.25 mm in diameter ...
... Network Sciences, Inc. (GNS) today announced that it ... University of California San Francisco Cancer ... drug development across several therapeutic areas. This collaboration ... of UCSF with the computational expertise and supercomputer-driven ...
... Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once ... world-leader and has a world-first to his credit. , ... Dallas, Texas ... http://www.RepairStemCells.org , a Dallas, Texas-based stem cell global public affairs organization founded ...
Cached Biology Technology:FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results 2RSCI Announces World-Leading Stem Cell Science Advisory Board 2RSCI Announces World-Leading Stem Cell Science Advisory Board 3
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the largest international study to date into the genetic basis ... disease and provide evidence that large-scale genetic studies can assist ... as rheumatoid arthritis. The study, conducted by Dr. Robert ... Institute in the USA and Dr. Yukinori Okada from the ...
... a recent study published in the Neural Regeneration ... Li and team from Zhongshan School of Medicine, Sun ... BACE1, the key enzyme in amyloid beta protein (Aβ) ... construct a short hairpin (shRNA) expression plasmid against the ...
... is in ideal cardiovascular health, according to the new CANHEART ... CMAJ ( Canadian Medical Association Journal ). Cardiovascular ... leading cause of death in Canada. "A large proportion ... trend has not changed in the past decade," says senior ...
Cached Biology News:Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: